Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1993-4-1
pubmed:abstractText
Regulation of gene expression by members of the NF-kappa B/rel transcription factor family is a central component of signal transduction pathways utilized by many cellular processes, including lymphocyte activation, embryonic development, and oncogenesis. The members of the NF-kappa B/rel transcription factor family are regulated by association with a family of inhibitor (I kappa B) proteins (I kappa B) proteins. To address the importance of the association between rel and I kappa B proteins for oncogenesis by rel proteins, we characterized rel-I kappa B interactions in chicken embryo fibroblasts (CEF) infected with retroviral vectors encoding the avian c-rel (p68c-rel), v-rel (p59v-rel), and I kappa B-beta (pp40I kappa B-beta) proteins. In these experiments, the p59v-rel:pp40I kappa B-beta ratio in coinfected CEF was nearly identical to the p59v-rel:pp40I kappa B-beta ratio in v-rel-transformed cells. The avian I kappa B-beta protein, pp40I kappa B-beta, was able to associate with both the nononcogenic p68c-rel and the oncogenic p59v-rel. Association of p68c-rel with pp40I kappa B-beta in coinfected CEF resulted in inhibition of the DNA-binding activity of p68c-rel. Anti-pp40I kappa B-beta serum was able to restore DNA binding to p68c-rel in the presence of high levels of pp40I kappa B-beta, indicating that pp40I kappa B-beta functions in a trans-acting manner to inhibit DNA binding by p68c-rel. In contrast, sequence-specific DNA binding by the oncogenic v-rel protein, p59v-rel, was not abolished by pp40I kappa B-beta in coinfected CEF. Anti-pp40I kappa B-beta serum did not immunoprecipitate the p59v-rel-DNA adduct or alter the electrophoretic mobility of the p59v-rel-DNA adduct, consistent with the idea that pp40I kappa B-beta and DNA are competitive inhibitors for the same or overlapping domains on rel proteins. Internal v-rel-derived sequences were identified that are responsible for loss of pp40I kappa B-beta-mediated inhibition of DNA binding by p59v-rel. Loss of pp40I kappa B-beta-mediated inhibition of DNA binding by recombinant v/c-rel proteins was not sufficient for oncogenic activation of c-rel. Instead, removal of C-terminal c-rel-derived sequences in addition to loss of pp40I kappa B-beta-mediated inhibition of DNA binding was required for oncogenic activation of c-rel. These results demonstrate the presence of an interaction between internal and C-terminal regions of the c-rel protein that is important for the ability of c-rel to regulate the proliferation of lymphoid cells.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1321284, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1339305, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1533881, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1566083, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1577270, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1732739, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1760839, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1829648, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1848011, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1876189, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1891714, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1903456, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1907941, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1944267, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-1992489, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2001591, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2006423, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2023921, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2111443, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2153225, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2157987, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2179815, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2180580, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2184941, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2189101, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2203531, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2204816, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2225078, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2234062, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2543940, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2555689, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2654811, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2665943, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2828665, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2846883, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-2856247, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-3004745, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-3129195, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-3140380, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-3796606, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-6090694, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-6312449, http://linkedlifedata.com/resource/pubmed/commentcorrection/8441412-6330534
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0270-7306
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1769-78
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:8441412-Animals, pubmed-meshheading:8441412-Base Sequence, pubmed-meshheading:8441412-Birds, pubmed-meshheading:8441412-Cell Transformation, Viral, pubmed-meshheading:8441412-Chick Embryo, pubmed-meshheading:8441412-DNA, Viral, pubmed-meshheading:8441412-DNA-Binding Proteins, pubmed-meshheading:8441412-Fibroblasts, pubmed-meshheading:8441412-Gene Expression Regulation, Neoplastic, pubmed-meshheading:8441412-I-kappa B Proteins, pubmed-meshheading:8441412-Molecular Sequence Data, pubmed-meshheading:8441412-Oncogene Proteins v-rel, pubmed-meshheading:8441412-Proto-Oncogene Proteins, pubmed-meshheading:8441412-Proto-Oncogene Proteins c-rel, pubmed-meshheading:8441412-Retroviridae, pubmed-meshheading:8441412-Retroviridae Proteins, Oncogenic, pubmed-meshheading:8441412-Spleen, pubmed-meshheading:8441412-Structure-Activity Relationship, pubmed-meshheading:8441412-Transcription Factor RelB, pubmed-meshheading:8441412-Transcription Factors
pubmed:year
1993
pubmed:articleTitle
Differential pp40I kappa B-beta inhibition of DNA binding by rel proteins.
pubmed:affiliation
Department of Biochemistry, University of Missouri-Columbia 65211.
pubmed:publicationType
Journal Article
More...